ArticleJournal of research in health sciences2016
Economic Burden of Thalassemia Major in Iran, 2015.
Article in Journal of research in health sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.The Cochrane database of systematic reviews · 2023Pooled it
- A Systematic Review and Meta-Analysis of Stature Growth Complications in β-thalassemia Major Patients.Annals of global health · 2021Pooled it
- Machine learning improves detection of alpha thalassemia carriers compared to clinical features.Scientific reports · 2025Article
- Epidemiology of the Incidence, Prevalence, and Mortality of Thalassemia in Iran: A Secondary Analysis of Global Burden of Disease 2019.Health science reports · 2025Article
- The direct costs of transfusion-dependent beta-thalassemia in Saudi Arabia: A cost of illness analysis study.Medicine · 2025Article
- Cost-Effectiveness Analysis of Different Prenatal Screening Strategies for the Prevention of Severe Thalassemia in Thailand.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Global Globin Network and adopting genomic variant database requirements for thalassemia.Database : the journal of biological databases and curation · 2024Article
- Systematic literature review of the indirect costs and humanistic burden of β-thalassemia.Therapeutic advances in hematology · 2024Review
- Economic burden of Thalassemia treatment: An analysis from the Vietnam Social Security perspective.PloS one · 2023Article
- Review
- Relationship between Serum Ferritin and Outcomes in β-Thalassemia: A Systematic Literature Review.Journal of clinical medicine · 2022Article
- Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study.BMC health services research · 2022Article
- Financial Burden in Families of Children with West Syndrome.Indian journal of pediatrics · 2022Article
- Predictors of health state utility values using SF-6D for Chinese adult patients with β-thalassemia major.Frontiers in public health · 2022Article
- Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study.Journal of pharmaceutical policy and practice · 2021Article
- Productivity Loss and Associated Costs Among Patients with Transfusion-Dependent Thalassemia in Dubai, United Arab Emirates.ClinicoEconomics and outcomes research : CEOR · 2021Article
- Changing patterns in the epidemiology of β-thalassemia.European journal of haematology · 2020Review
- Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective.Mediterranean journal of hematology and infectious diseases · 2020Article
- Serum ferritin levels and irregular use of iron chelators predict liver iron load in patients with major beta thalassemia: a cross-sectional study.Croatian medical journal · 2019Article
- Economic Evaluation of Chelation Regimens for β-Thalassemia Major: a Systematic Review.Mediterranean journal of hematology and infectious diseases · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor Thalassemia is an autosomal recessive disease with complications, mortality and serious pathology. Today, the life expectancy of patients with major thalassemia has increased along with therapeutic advances. Therefore, they need lifelong care, and caring for them would incur many costs. Being aware of the patients' costs can be effective for controlling and managing the costs and providing efficient treatments for the care of patients. Hence, this study was conducted to estimate the economic burden of the patients with major thalassemia.
methodsTotally, 198 patients with major thalassemia were randomly selected from among the patients with major thalassemia in Tehran, Iran in 2015. The economic burden of the patients was estimated from a social perspective and through a bottom-up, prevalence-based approach.
resultsThe average annual cost per patient was estimated $ 8321.8 regardless of the cost of lost welfare. Of this amount, $ 7286.8 was related to direct medical costs, $ 461.4 to direct non-medical costs, and $ 573.5 to indirect costs. In addition, the annual cost per patient was estimated $ 1360.5 due to the distress caused by the disease
conclusionsConsidering the high costs of the treatment of patients with major thalassemia, adopting new policies to reduce the costs that patients have to pay seems necessary. In addition, making new decisions regarding thalassemia screening, even with higher costs than the usual screening costs, can be useful since the costs of treatment are high.
Indexed as
Identifiers
27840337PMC7191027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.